BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ueda T, Chikuie N, Takumida M, Furuie H, Kono T, Taruya T, Hamamoto T, Hattori M, Ishino T, Takeno S. Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with clinical outcome in recurrent or metastatic head and neck cancer patients treated with nivolumab. Acta Otolaryngol 2020;140:181-7. [PMID: 31825711 DOI: 10.1080/00016489.2019.1699250] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Wan YN, Chen HM, Liu XF, Gu WG, Lu YY. Elevated pretreatment neutrophil-to-lymphocyte ratio indicate low survival rate in apatinib-treated patients with non-small cell lung cancer: A STROBE-compliant article. Medicine (Baltimore) 2022;101:e32043. [PMID: 36451494 DOI: 10.1097/MD.0000000000032043] [Reference Citation Analysis]
2 Zhang Z, Xie T, Qi C, Zhang X, Shen L, Peng Z. Peripheral Blood Biomarkers Predictive of Efficacy Outcome and Immune-Related Adverse Events in Advanced Gastrointestinal Cancers Treated with Checkpoint Inhibitors. Cancers 2022;14:3736. [DOI: 10.3390/cancers14153736] [Reference Citation Analysis]
3 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
4 Weng J, Li S, Zhu Z, Liu Q, Zhang R, Yang Y, Li X. Exploring immunotherapy in colorectal cancer. J Hematol Oncol 2022;15:95. [PMID: 35842707 DOI: 10.1186/s13045-022-01294-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
5 Boscolo-rizzo P, D’alessandro A, Polesel J, Borsetto D, Tofanelli M, Deganello A, Tomasoni M, Nicolai P, Bossi P, Spinato G, Menegaldo A, Ciorba A, Pelucchi S, Bianchini C, Cazzador D, Ramaciotti G, Lupato V, Giacomarra V, Molteni G, Marchioni D, Fabbris C, Occhini A, Bertino G, Fussey J, Tirelli G. Different inflammatory blood markers correlate with specific outcomes in incident HPV-negative head and neck squamous cell carcinoma: a retrospective cohort study. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09327-4] [Reference Citation Analysis]
6 Takenaka Y, Oya R, Takemoto N, Inohara H. Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta-analysis. Head Neck 2022. [PMID: 35146824 DOI: 10.1002/hed.26997] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Yildiz E. Neutrophil Counts and Rates in Otorhinolaryngology. Inflammation in the 21st Century 2022. [DOI: 10.5772/intechopen.93457] [Reference Citation Analysis]
8 Pamukcuoglu M, Baysal NA, Pepeler MS. The infection rate in new diagnosis and relapsed/refractory multiple myeloma patients who had bortezomib-based chemotherapy and relationship between development of infection and lymphocyte/monocyte ratio. The European Research Journal 2021. [DOI: 10.18621/eurj.855510] [Reference Citation Analysis]
9 Fan X, Wang D, Zhang W, Liu J, Liu C, Li Q, Ma Z, Li H, Guan X, Bai Y, Yang J, Lou C, Li X, Wang G, Li Z. Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti-PD-1 Therapy. Front Cell Dev Biol 2021;9:638312. [PMID: 33791296 DOI: 10.3389/fcell.2021.638312] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
10 Nakazawa Y, Gannichida A, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Involvement of Neutrophil-lymphocyte Ratio in Nivolumab Therapy-induced Hypothyroidism. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 2020;46:481-8. [DOI: 10.5649/jjphcs.46.481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Pang Y, Shao H, Yang Z, Fan L, Liu W, Shi J, Wang Y, Han Y, Yang L. The (Neutrophils + Monocyte)/Lymphocyte Ratio Is an Independent Prognostic Factor for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients Treated With BCD Regimen. Front Oncol 2020;10:1617. [PMID: 32984029 DOI: 10.3389/fonc.2020.01617] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Zhou S, Yuan H, Wang J, Hu X, Liu F, Zhang Y, Jiang B, Zhang W. Prognostic value of systemic inflammatory marker in patients with head and neck squamous cell carcinoma undergoing surgical resection. Future Oncol 2020;16:559-71. [PMID: 32166977 DOI: 10.2217/fon-2020-0010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]